Guggenheim analyst Subbu Nambi raised the firm’s price target on Guardant Health (GH) to $115 from $85 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Guardant Health downgraded to In Line from Outperform at Evercore ISI
- Guardant Health price target raised to $125 from $100 at Canaccord
- Guardant Health price target raised to $120 from $100 at Mizuho
- Guardant Health price target raised to $120 from $100 at BofA